A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial.

This document provides information about a clinical trial for the treatment of acute myeloid leukemia (AML) in older and unfit patients with FLT3 mutations. The trial aims to compare two treatment approaches: azacitidine and venetoclax versus azacitidine, venetoclax, and gilteritinib. Azacitidine activates cancer suppressor genes, venetoclax blocks a protein needed for cancer cell survival, and gilteritinib blocks the action of a substance that helps cancer cells multiply. The trial is not yet recruiting participants and is being conducted by the National Cancer Institute (NCI). The estimated enrollment is 147, and the primary completion date is projected to be October 31, 2025. [Extracted from the article]